Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugenia Quiros-Roldan

Showing results (171-180 of 209) with videos related to

Pageof 21
Sort By:
HIV Clinical Trials|November 9, 2012
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavirDaria Gotti, Bruno Mario Cesana, Laura Albini, et al.
International Journal of STD & AIDS|January 8, 2025
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohortAndrea Antinori, Giulia Marchetti, Vincenzo Esposito, et al.
Plos One|April 25, 2014
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter studyDaria Gotti, Elena Raffetti, Laura Albini, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 14, 2011
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenzLaura Albini, Bruno Mario Cesana, Davide Motta, et al.
Open Forum Infectious Diseases|August 13, 2025
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997-2022: Data From the Icona CohortAndrea Giacomelli, Simone Lanini, Andrea De Vito, et al.
International Journal of Antimicrobial Agents|January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohortRoberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
BMC Infectious Diseases|July 16, 2005
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Salvatore Casari, et al.
Medicine|July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort studyEmanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
BMC Infectious Diseases|February 16, 2012
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà, Davide Motta, Marco Borderi, et al.
Journal of Global Antimicrobial Resistance|April 12, 2025
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitorsDaniele Armenia, Greta Marchegiani, Daniele Spalletta, et al.
Pageof 21

Showing results (171-180 of 209) with videos related to

Sort By:
Pageof 21
HIV Clinical Trials|November 9, 2012
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavirDaria Gotti, Bruno Mario Cesana, Laura Albini, et al.
International Journal of STD & AIDS|January 8, 2025
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohortAndrea Antinori, Giulia Marchetti, Vincenzo Esposito, et al.
Plos One|April 25, 2014
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter studyDaria Gotti, Elena Raffetti, Laura Albini, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 14, 2011
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenzLaura Albini, Bruno Mario Cesana, Davide Motta, et al.
Open Forum Infectious Diseases|August 13, 2025
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997-2022: Data From the Icona CohortAndrea Giacomelli, Simone Lanini, Andrea De Vito, et al.
International Journal of Antimicrobial Agents|January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohortRoberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
BMC Infectious Diseases|July 16, 2005
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Salvatore Casari, et al.
Medicine|July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort studyEmanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
BMC Infectious Diseases|February 16, 2012
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà, Davide Motta, Marco Borderi, et al.
Journal of Global Antimicrobial Resistance|April 12, 2025
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitorsDaniele Armenia, Greta Marchegiani, Daniele Spalletta, et al.
Pageof 21